



March 10, 2025

Dear EML Secretariat,

On behalf of [Miles for Migraine](https://milesformigraine.org), one of leading international non-profit organizations who supports people with Migraine, Cluster Headache, Trigeminal Neuralgia and other headache diseases, dedicated to supporting individuals with migraine and other headaches.

We have read with extreme interest the applications:

[A.10 eletriptan naproxen, migraine

A.13 fremanezumab, high frequency and chronic migraine

I.2 amitriptyline - migraine prophylaxis

I.3 bisoprolol - migraine prophylaxis

I.7 Ibuprofen - acute migraine treatment

I.10 Prednisolone, sumatriptan and verapamil - cluster headache]

I write in support of such applications because they address an important need in the general population. Migraine and cluster headache are highly disabling chronic conditions, underdiagnosed and undertreated.

The addition of more effective drugs for their management is an important step toward better care in many countries.

Our organization is committed to supporting this initiative and is available to provide any further information or assistance. We look forward to the positive impact this development will have on the global health landscape.

Sincerely,

Shirley Kessel

Executive Director



16 Cilley Hill Road, Jericho, VT 05465 • P: 215.880.1150
Eileen@milesformigraine.org • www.milesformigraine.org • [#milesformigraine](https://twitter.com/milesformigraine)

Miles for Migraine is a 501(c)(3) non-profit organization • TAX ID# 01-0910-791